Argolyn Bioscience

Biotechnology company Argolyn Bioscience, Inc. discovers and develops peptide candidate drugs for the treatment of psychiatric disorders, pain, and other serious diseases and conditions. The company's products are based on amino acid analog substitution technology. The company’s product pipeline includes ABS201 for schizophrenia and ABS212 for pain.